Sarcoidosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Sarcoidosis
Emerging Therapy and TPP Insights
Thelansis’s “Sarcoidosis
Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides
a comprehensive analysis of the emerging competitive landscape, unmet needs,
target product profiles (TPPs), trial designs, and KOL insights on key emerging
therapies and key drug development opportunities in the indication.
Sarcoidosis
Overview
Sarcoidosis
is a multisystem granulomatous disorder of incompletely understood aetiology,
characterised by the pathological accumulation of non-caseating granulomas —
composed of activated macrophages, epithelioid cells, and CD4+ T-lymphocytes —
in affected organs, driven by dysregulated innate and adaptive immune responses
to unidentified antigenic triggers in genetically susceptible individuals. The
lungs and intrathoracic lymph nodes are involved in over 90% of cases, with
frequent additional involvement of skin, eyes, liver, spleen, heart, and
nervous system. Patients present heterogeneously — ranging from asymptomatic
incidental discovery to Löfgren syndrome, an acute, typically self-limiting
presentation of bilateral hilar lymphadenopathy, erythema nodosum, and
arthritis — alongside chronic dyspnoea, dry cough, fatigue, and organ-specific
manifestations. Diagnosis integrates clinical, radiological, and
histopathological findings; chest imaging demonstrating bilateral hilar
lymphadenopathy, elevated serum ACE and sIL-2R as supportive biomarkers, and
biopsy confirming non-caseating granulomas while excluding infectious and
malignant mimics. Corticosteroids remain the therapeutic cornerstone for
symptomatic or progressive disease, with methotrexate and azathioprine as
steroid-sparing agents for chronic disease. Refractory cases may benefit from
hydroxychloroquine or anti-TNF biologics including infliximab. Cardiac and
neurosarcoidosis demand particularly vigilant monitoring given life-threatening
complication risk. Prognosis varies considerably; spontaneous remission occurs
in many, while chronic progressive disease necessitates long-term
multidisciplinary surveillance and patient-centred supportive management.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Read more: Sarcoidosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Comments
Post a Comment